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Patient characteristics, duration of nebulised amiloride and TOBI® therapy;
adherence, and eradication rate.
Patient Genomovar Age
(years)
Duration of
infection
(months)
Duration of
amiloride
and TOBI®
(weeks)
Adherence
(bottle
count, %)
Eradication
success
(Y/N)
A IV 14 1 16 96.4 Y
B II 12 108 10 90.91 N
C IIIA ET-12 16 7 11 56.55 N
D IIIA ET-12 9 14 12 93.18 N
E II 15 128 19 36.43 N
F II 16 44 10 6.88 N
G IIIA ET-12 14 14 43 62.79 NCan Burkholderia cepacia complex be eradicated with
nebulised Amiloride and TOBI®?
Sir,
Burkholderia cepacia complex (Bcc) is an important gram-
negative pathogen for people with cystic fibrosis (CF). Bur-
kholderia multivorans (genomovar II), is the most prevalent
species in the United Kingdom and thought to be mainly
acquired from the environment. Burkholderia cenocepacia
(particularly IIIA) is more commonly associated with Cepacia
syndrome, and is highly transmissible, usually acquired by
cross-infection from other patients with CF [1]. Bcc is often
inherently resistant to multiple antibiotics and is associated with
accelerated decline in lung function and nutritional status [2].
Retrospective data from a large United Kingdom adult CF
Centre reported that once Bcc was acquired chronic infection
developed in approximately 50% of cases of B. multivorans
infection and 94% of B. cenocepacia infection, despite treatment
[2].
In vitro studies demonstrate synergy between amiloride, and
similar adjunctive compounds, and tobramycin against a
number of Bcc isolates [3,4]. A case series of four adult CF
patients with early growth of Bcc reported successful
eradication using nebulised amiloride and tobramycin, com-
menced within two months of initial growth, in three cases (one
B. cenocepacia IIIA; one Burkholderia ambifaria (genomovar
VII), one unclear) [5]. We describe our clinical experience of
twice daily nebulised amiloride followed by nebulised TOBI®
to eradicate Bcc infection in children with CF.
Seven children attending our CF Centre (5 female; mean age
15.2 years; range 12–16 years), confirmed by reference labo-
ratory to have sputum samples positive for Bcc (three B.
multivorans, three B. cenocepacia IIIA ET-12 strain, and one
Burkholderia stabilis) within the previous 4 weeks, were
invited to receive nebulised amiloride (1.5 mg in 5 ml 0.45%
Sodium Chloride; Stockport Pharmaceuticals, NHS, UK),
followed by nebulised TOBI® (300 mg in 5 ml; Novartis,
UK). Mean duration of Bcc infection was 14 months (range 1–
128 months). All Bcc isolates demonstrated resistance to
tobramycin in vitro. Patient characteristics and results are
shown in Table 1. Both medications were taken via
eFlowrapid® (Pari GmbH, Starnberg, Germany), with the
intention to administer the regimen for 6 months. Peak flow
and FEV1 were measured daily at home using a PIKO-1
®
(Ferraris Respiratory, Hertford, UK). Sputum samples were
collected at routine clinic visits every 4–8 weeks. Adherence
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amiloride bottles.
Eradication of Bcc occurred in one patient who had had a
first growth of B. stabilis. The regimen was well-tolerated.
There was no significant change in mean FEV1 from the start to
the end of treatment. Only one patient completed 6 months of
treatment. Reasons for early discontinuation were (i) success-
ful eradication, (ii) exacerbation or new growth of P.
aeruginosa necessitating a change in nebulised antibiotic
regimen and (iii) excessive burden of treatment. One patient
continued treatment for 10 months because of the perceived
initial clinical benefits, but ultimately discontinued because
of continued growth of Bcc. Parent/patient adherence diaries
were incomplete.
In our experience this treatment regimen of nebulised
amiloride and TOBI® in combination was unsuccessful at
eradicating B. multivorans or B. cenocepacia IIIA in patients
who had been infected for at least 7 months. Concordance as
measured by bottle count was b75% in 4 of the 7 patients. One
patient demonstrated associated successful eradication of Bcc
genomovar IV and remains free 18 months later. However,
treatment was initiated within 4 weeks of infection and the natural
history of genomovar IV infections is not well-characterised.
Our study contrasts with the previous report by Middleton
et al., where all the subjects had only recently isolated Bcc
for the first time, and where the amiloride and nebulised
tobramycin were given three times a day, rather than twice [5].
When considered with the previously published data [3–5], our
findings suggest that nebulised amiloride and TOBI® may be
effective for early eradication of Bcc within 2 months of initiald by Elsevier B.V. All rights reserved.
74 Letter to the Editorinfection, but do not appear effective to eradicate chronic Bcc
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